GSK Pharma recommends ₹57 dividend, sets AGM date

GlaxoSmithKline Pharmaceuticals Limited has recommended a dividend of ₹57 per share, equivalent to 570% on a face value of ₹10 each, for the financial year ended March 31, 2026. The payout, subject to shareholder approval, will be made on or after June 30, 2026. To be eligible for the dividend, shareholders must be listed in the Register of Members as of the record date, Friday, May 29, 2026.

The company announced that its 101st Annual General Meeting (AGM) will be held on Tuesday, June 30, 2026, at 11.00 a.m. via Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The meeting will be conducted without the physical presence of shareholders at a common venue, in compliance with the Companies Act, 2013, and relevant SEBI (Listing Regulations) and Ministry of Corporate Affairs circulars.

Attendance of shareholders participating through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013. The Notice of the AGM and the Annual Report for FY26 are being sent electronically to shareholders with registered email addresses. Those without registered emails will receive a letter containing the weblink to the reports from the Registrar & Share Transfer Agent.

The company has also provided instructions for shareholders to register or update their email addresses and bank account mandates. Shareholders holding shares in dematerialized form must update details with their Depository Participant, while those with physical holdings must submit the prescribed ISR-1 form to KFin Technologies Limited.

Holding Type	Action Required
Dematerialized Holding	Register/update details in demat account via Depository Participant
Physical Holding	Submit ISR-1 form to KFin Technologies Limited

Pursuant to SEBI directives effective November 18, 2025, dividend payments will be processed exclusively in electronic mode, discontinuing the use of dividend warrants or cheques. The company noted that dividend income is taxable in the hands of shareholders, and tax will be deducted at source at prescribed rates as per the Finance Act, 2020.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE159A01016/6da94d8d21ed428c.pdf

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.66%	-5.64%	-7.27%	-13.99%	-33.23%	+42.48%

GlaxoSmithKline Pharmaceuticals Limited has announced the resignation of Dr. Simrat Sohal from the position of Compliance Officer and Senior Management Personnel. The resignation is effective from the close of business hours on August 5, 2026, as she intends to pursue opportunities outside the organization. Consequently, she will cease to be a Senior Management Personnel of the company effective the said date.

The company informed the stock exchanges regarding this change in senior managerial personnel in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was also made in accordance with SEBI Circular Nos. CIR/CFD/CMD/412015 dated September 9, 2015 and Exchange Circular List/Comp/14/2018-19 dated June 20, 2018.

Resignation Details

The filing provided specific particulars regarding the cessation of Dr. Sohal's role within the company. The reason for the change was cited as a resignation to pursue external opportunities.

Particulars	Details
Reason for change	Resignation
Date of cessation	Effective close of business hours of 5 August 2026
Brief Profile	Not Applicable
Disclosure of relationship between Directors	Not Applicable

Dr. Simrat Sohal had submitted her resignation notice on May 19, 2026, confirming her final working day as August 5, 2026. She expressed her commitment to ensuring a smooth transition and completing all handover responsibilities during her notice period. The acceptance of the resignation was confirmed by the company management.